Incretin & satiety signalling
One of 4 mechanistic pathways to 📉 Metabolic health & insulin sensitivity · 18 options
GLP-1 and GIP are released by the gut in response to food. They amplify glucose-dependent insulin secretion — meaning they raise insulin only when glucose is high, which is why they don't cause hypoglycaemia the way sulfonylureas do.
The monitoring panel for anyone on a GLP-1. Lipase and amylase are there for the pancreatitis signal, and thyroid because of the medullary carcinoma contraindication — both are on the label and rarely tracked.
HbA1c (Hemoglobin A1c)Fasting InsulinC-Peptide, SerumLipaseAmylaseComprehensive Metabolic Panel (CMP)TSH (Thyroid-Stimulating Hormone)💉 On a GLP-1 (Semaglutide / Tirzepatide) covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Semaglutide
GLP-1 agonism improves HbA1c substantially and has cardiovascular outcome data in SELECT and SUSTAIN-6 — benefit beyond glucose control.
💉 Tirzepatide
Dual GIP/GLP-1 with the strongest glycaemic and weight results in head-to-head trials.
💉 Retatrutide
Triple agonism adding glucagon-mediated hepatic fat oxidation — particularly relevant to fatty liver.
💉 Survodutide
GLP-1/glucagon dual with hepatic fat reduction as a specific target.
💉 Pemvidutide
Tuned deliberately toward liver fat and lean-mass preservation.
💉 Mazdutide
GLP-1/glucagon dual with substantial Chinese trial data.
💉 Orforglipron
Oral non-peptide GLP-1 — same mechanism, no injection.
💉 Ecnoglutide
Long-acting GLP-1 with a cAMP-biased signalling profile.
💉 Dulaglutide
Weekly GLP-1 with cardiovascular outcome data in REWIND.
💉 Liraglutide
Daily GLP-1 with the LEADER outcome trial behind it.
💉 Exenatide
The first-generation GLP-1, derived from Gila monster venom. Mechanistically identical to the modern agents and clinically outclassed by them on both dosing and effect size.
💉 Amycretin
GLP-1 plus amylin in one molecule; early human data is promising.
💉 Pramlintide
Amylin analog that slows gastric emptying and suppresses inappropriate post-meal glucagon — an underused mechanism.
💉 Cagrilintide
Long-acting amylin analog, usually paired with a GLP-1.
💉 Eloralintide
Selective amylin receptor agonist aiming for satiety with less nausea.
🧬 GLP-1 Support Stack
Covers the muscle-loss, constipation and micronutrient issues that come with incretin therapy.
🧬 Fiber (FiberMend)
Fermentable fibre raises endogenous GLP-1 through colonic short-chain fatty acid production — the physiological version of the same pathway.
🧬 Partially Hydrolysed Guar Gum (PHGG)
Viscous fibre that slows gastric emptying without the fermentation load.
The other 3 routes to metabolic health & insulin sensitivity
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
Want the protocols behind these?
Dosing schedules, stacking, cycle timing and Coach Cam's notes live inside the Academy — plus the full interactive Vault.
Join the Academy — $10/mo →← Open this pathway in the interactive Vault
Frequently asked questions
GLP-1 and GIP are released by the gut in response to food. They amplify glucose-dependent insulin secretion — meaning they raise insulin only when glucose is high, which is why they don't cause hypoglycaemia the way sulfonylureas do.
18 options are mapped to this pathway in the Vault, including Semaglutide, Tirzepatide, Retatrutide, Survodutide. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 15 carry clinical validation and 3 are mechanistic predictions.
The monitoring panel for anyone on a GLP-1. Lipase and amylase are there for the pancreatitis signal, and thyroid because of the medullary carcinoma contraindication — both are on the label and rarely tracked. The markers worth checking are HbA1c (Hemoglobin A1c), Fasting Insulin, C-Peptide, Serum, Lipase.
Unproven is not the same as ineffective. Of the 18 options on this pathway, 15 have clinical validation and 3 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.